Novartis Pharma: The Business Unit Model Custom Case Solution & Analysis

1. Evidence Brief

Financial Metrics

Revenue Performance: Novartis Pharma sales reached 12.3 billion dollars in 2001, representing a 14 percent increase over the previous year.
R&D Investment: Research and development spending was maintained at approximately 18 percent of total sales, significantly higher than the industry average of 13 to 15 percent.
Operating Income: Pharma operating income grew by 15 percent in 2001, reaching 3.5 billion dollars.
Marketing and Distribution: Marketing, Sales, and General Administration (MS&A) expenses stood at 33 percent of sales.

Operational Facts

Organizational Structure: Transitioned from a functional model to five distinct Business Units (BUs): Primary Care, Oncology, Transplantation, Ophthalmics, and Mature Products.
Headcount: The global sales force expanded to approximately 20,000 representatives by 2002.
Product Pipeline: The portfolio included 75 projects in clinical development and 55 in the pre-clinical phase.
Shared Services: Global functions such as R&D, Finance, and Human Resources remained centralized to serve all BUs.

Stakeholder Positions

Daniel Vasella (Group CEO): Prioritizes performance-driven culture and scientific excellence. Supported the BU model to increase accountability.
Thomas Ebeling (Pharma CEO): Former PepsiCo executive. Advocates for consumer-style marketing, brand ownership, and decentralized P&L responsibility.
Business Unit Heads: Demand greater control over R&D priorities and resource allocation to meet specific market targets.
R&D Leadership: Expresses concern that BU-driven priorities might favor short-term line extensions over long-term breakthrough science.

Information Gaps

Unit-Level Margins: The case does not provide individual operating margins for the Transplantation or Ophthalmics units.
Retention Data: Specific turnover rates for R&D scientists following the 2000 reorganization are absent.
Competitor Cost Structures: Direct comparison of MS&A spend against specific rivals like Pfizer or GlaxoSmithKline is limited.

2. Strategic Analysis

Core Strategic Question

How should Novartis balance Business Unit autonomy with the need for global scale and integrated R&D to sustain industry-leading growth?

Structural Analysis

Applying a Value Chain Analysis reveals that the primary source of competitive advantage has shifted from pure R&D to the interface between R&D and Marketing. Under the functional model, this interface was slow. The BU model addresses this by aligning marketing strategy with specific therapeutic areas. However, the BCG Matrix application shows a portfolio imbalance: Primary Care serves as the Cash Cow, while Oncology is the high-growth Star. The Transplantation unit faces maturing markets, requiring a different operational logic than the high-growth segments.

Strategic Options

Option 1: Full BU Integration. Decentralize R&D and manufacturing into each BU.
- Rationale: Maximum speed and absolute P&L accountability.
- Trade-offs: Duplication of costs and loss of scientific cross-pollination.
- Resources: Significant capital for redundant infrastructure.
Option 2: Refined Hybrid Model (Recommended). Maintain centralized R&D and Shared Services but implement a contract-based Service Level Agreement (SLA) between BUs and R&D.
- Rationale: Preserves scale efficiencies while ensuring R&D remains responsive to market needs.
- Trade-offs: Increased administrative complexity in internal negotiations.
- Resources: New internal accounting and performance tracking systems.
Option 3: Functional Re-centralization. Return to a functional structure with BU-specific marketing teams only.
- Rationale: Focuses on cost control and scientific focus.
- Trade-offs: Reintroduces silos and slows market response times.
- Resources: Minimal new capital; high organizational disruption.

Preliminary Recommendation

Novartis must pursue Option 2. The complexity of modern medicine requires deep therapeutic specialization (the BU benefit), but the underlying science of drug discovery often yields discoveries applicable across multiple units. A hybrid model protects this scientific serendipity while forcing BU heads to compete for R&D resources based on rigorous commercial business cases.

3. Implementation Roadmap

Critical Path

Month 1: Define the internal pricing mechanism for R&D services. BU heads must know the cost of the research they commission.
Month 2: Establish the Portfolio Review Committee (PRC) with equal representation from BU commercial leads and R&D scientists.
Month 3: Realign the Pharma Executive Committee (PEC) incentives to include 30 percent weight on cross-BU performance to discourage resource hoarding.

Key Constraints

Leadership Talent: The model requires BU heads who are both scientific experts and commercial operators. This dual-competency talent pool is shallow.
Data Transparency: Current IT systems do not allow for granular tracking of R&D hours spent per BU project, making internal billing difficult.

Risk-Adjusted Implementation Strategy

The transition will occur in three phases. Phase one focuses on the Oncology and Primary Care units, which represent the bulk of revenue. Phase two expands to smaller units. Phase three integrates the Mature Products unit into a low-cost, high-efficiency model. To mitigate execution friction, a contingency fund of 5 percent of the MS&A budget will be held at the Pharma CEO level to address unforeseen integration gaps or talent acquisition needs.

4. Executive Review and BLUF

BLUF

Novartis should commit to the Business Unit model but must formalize the relationship between BUs and centralized R&D through internal market mechanisms. The current model risks scientific fragmentation. By treating R&D as a shared strategic asset that BUs contract with, Novartis can maintain scale while driving local accountability. Success depends on shifting from a culture of consensus to one of internal competition for resources based on projected ROI. This transition must be completed within 12 months to protect the current pipeline momentum.

Dangerous Assumption

The analysis assumes that consumer marketing principles from the beverage industry can be directly applied to the pharmaceutical sector without degrading the scientific rigor required for regulatory approval and physician trust. If the BUs prioritize short-term marketing spend over long-term clinical trial depth, the brand equity of Novartis will erode.

Unaddressed Risks

Regulatory Shift: Increased scrutiny from the FDA or EMA on therapeutic-specific marketing could render the BU-heavy sales structure inefficient or legally vulnerable. (Probability: Medium; Consequence: High).
R&D Brain Drain: Top-tier scientists may leave if they feel their work is dictated by commercial BU heads rather than scientific potential. (Probability: High; Consequence: Critical).

Unconsidered Alternative

The team did not evaluate a Geographic-first structure. In emerging markets, the BU-specific sales force is often too thin to be effective. A geographic model in those regions, combined with a BU model in developed markets, might optimize global coverage better than a blanket BU approach.